Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Antares Pharma (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 560,486
  • Shares Outstanding, K 157,440
  • Annual Sales, $ 54,520 K
  • Annual Income, $ -16,740 K
  • 36-Month Beta 0.39
  • Price/Sales 10.19
  • Price/Cash Flow N/A
  • Price/Book 22.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.02
  • Number of Estimates 5
  • High Estimate -0.01
  • Low Estimate -0.03
  • Prior Year -0.03
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.20 +6.61%
on 09/24/18
3.93 -13.19%
on 10/02/18
+0.05 (+1.53%)
since 09/18/18
3-Month
2.54 +34.31%
on 07/31/18
3.93 -13.19%
on 10/02/18
+0.69 (+25.42%)
since 07/18/18
52-Week
1.58 +115.92%
on 11/08/17
3.93 -13.19%
on 10/02/18
+1.18 (+52.98%)
since 10/18/17

Most Recent Stories

More News
Global Transdermal Drug Delivery Market 2016-2018 & 2024 Featuring Antares Pharma, Bayer, ANI Pharmaceuticals, Novartis & Janssen Pharmaceuticals

The "Transdermal Drug Delivery Market: Global Demand Analysis & Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering.

ATRS : 3.41 (-4.21%)
NVS : 85.81 (+0.62%)
Auto-injectors Market Global Forecast by Application, Product Types, Usability, Distribution Channels Regions, Companies

Auto-injectors Market Global Forecast by Application (Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis, Others), Product Types (Prefilled, Fillable), Usability (Reusable, Disposable), Distribution...

BAYRY : 22.3450 (-0.20%)
ATRS : 3.41 (-4.21%)
NVS : 85.81 (+0.62%)
AMGN : 201.47 (-0.64%)
Antares Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2,...

ATRS : 3.41 (-4.21%)
Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector

Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that the U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries, Ltd.'s ("Teva") epinephrine auto injector drug-device...

ATRS : 3.41 (-4.21%)
Today's Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma

NEW YORK, NY / ACCESSWIRE / August 14, 2018 / There was no news to explain the sudden jump shares of Xenetic Biosciences saw in Monday's trading session. Shares of Antares Pharma also climbed higher despite...

XBIO : 2.56 (+7.42%)
ATRS : 3.41 (-4.21%)
Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to a Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Antares Pharma, Inc. (NasdaqCM: ATRS) have filed a class action complaint against the company's officers...

ATRS : 3.41 (-4.21%)
Antares Pharma: 2Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Tuesday reported a loss of $4.5 million in its second quarter.

ATRS : 3.41 (-4.21%)
Antares Pharma Reports Second Quarter 2018 Operating and Financial Results

Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today reported operating and financial results for the second quarter ended June 30, 2018. The Company reported revenue of $14.2 million and a net loss...

ATRS : 3.41 (-4.21%)
Antares Pharma to Report Second Quarter 2018 Financial and Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2018 financial results and recent operating progress before the market opens on Tuesday, August 7, 2018. Management...

ATRS : 3.41 (-4.21%)
Consolidated Research: 2018 Summary Expectations for South Jersey Industries, Cedar Realty Trust, Antares Pharma, Q2, Cree, and HCI Group -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of South Jersey Industries, Inc....

CDR : 3.94 (-1.99%)
CREE : 37.73 (-4.38%)
SJI : 34.99 (-0.40%)
ATRS : 3.41 (-4.21%)
QTWO : 51.41 (-2.63%)
HCI : 43.33 (-0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATRS with:

Business Summary

Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes...

See More

Key Turning Points

2nd Resistance Point 3.70
1st Resistance Point 3.63
Last Price 3.41
1st Support Level 3.46
2nd Support Level 3.36

See More

52-Week High 3.93
Last Price 3.41
Fibonacci 61.8% 3.03
Fibonacci 50% 2.76
Fibonacci 38.2% 2.48
52-Week Low 1.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar